Primary systemic therapy in HER2-amplified breast cancer: a clinical review
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Primary systemic therapy in HER2-amplified breast cancer: a clinical review
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 12, Issue 8, Pages 1005-1013
Publisher
Informa UK Limited
Online
2012-10-03
DOI
10.1586/era.12.62
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epirubicin: Is it like doxorubicin in breast cancer? A clinical review
- (2012) Mustafa Khasraw et al. BREAST
- S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).
- (2012) A Schneeweiss et al. CANCER RESEARCH
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- P301 Addition of pertuzumab (P) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: Result of a randomised phase II study (NEOSPHERE)
- (2011) L. Gianni et al. BREAST
- Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer
- (2011) Denise A. Yardley et al. Clinical Breast Cancer
- Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study
- (2011) V. Semiglazov et al. EJSO
- 5013 ORAL FDG-PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-positive Breast Cancer Patients: the Neo-ALTTO Study Results
- (2011) C. Gamez et al. EUROPEAN JOURNAL OF CANCER
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
- (2010) G. von Minckwitz et al. ANNALS OF ONCOLOGY
- A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients
- (2010) Jean-Yves Pierga et al. BREAST CANCER RESEARCH AND TREATMENT
- Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
- (2010) Isabell Witzel et al. BREAST CANCER RESEARCH AND TREATMENT
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review
- (2010) L. S. Rosen et al. ONCOLOGIST
- The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?
- (2010) Mustafa Khasraw et al. Current Oncology Reports
- Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study
- (2009) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
- (2009) Guido Sauter et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
- (2008) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial
- (2008) G. von Minckwitz et al. JNCI-Journal of the National Cancer Institute
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started